Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1992 1
1995 1
1999 1
2003 3
2004 3
2006 2
2007 1
2008 1
2009 2
2011 3
2012 11
2013 12
2014 11
2015 21
2016 13
2017 10
2018 10
2019 14
2020 4
2021 4
2022 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25074688

112 results

Results by year

Filters applied: . Clear all
Page 1
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.
Genovese MC, van der Heijde DM, Keystone EC, Spindler AJ, Benhamou C, Kavanaugh A, Fudman E, Lampl K, O'Brien C, Duffield EL, Poiley J, Weinblatt ME. Genovese MC, et al. J Rheumatol. 2014 Nov;41(11):2120-8. doi: 10.3899/jrheum.140238. Epub 2014 Sep 15. J Rheumatol. 2014. PMID: 25225285 Clinical Trial.
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Weinblatt ME, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A, Millson DS, Leon G, Wang M, van der Heijde D. Weinblatt ME, et al. Arthritis Rheumatol. 2014 Dec;66(12):3255-64. doi: 10.1002/art.38851. Arthritis Rheumatol. 2014. PMID: 25223724 Clinical Trial.
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH. Fleischmann R, et al. Arthritis Rheum. 2012 Mar;64(3):617-29. doi: 10.1002/art.33383. Arthritis Rheum. 2012. PMID: 21952978 Free article. Clinical Trial.
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.
Kitas GD, Abreu G, Jedrychowicz-Rosiak K, Miller JL, Nakov R, Panfilov S, Vencovsky J, Wang M, Weinblatt ME, White WB. Kitas GD, et al. J Am Soc Hypertens. 2014 Nov;8(11):780-90. doi: 10.1016/j.jash.2014.08.013. Epub 2014 Sep 4. J Am Soc Hypertens. 2014. PMID: 25455003 Clinical Trial.
Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.
Genovese MC, Hsia E, Belkowski SM, Chien C, Masterson T, Thurmond RL, Manthey CL, Yan XD, Ge T, Franks C, Greenspan A. Genovese MC, et al. J Rheumatol. 2015 Oct;42(10):1752-60. doi: 10.3899/jrheum.141580. Epub 2015 Aug 1. J Rheumatol. 2015. PMID: 26233509 Free article. Clinical Trial.
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Westhovens R, Taylor PC, Alten R, Pavlova D, Enríquez-Sosa F, Mazur M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P. Westhovens R, et al. Ann Rheum Dis. 2017 Jun;76(6):998-1008. doi: 10.1136/annrheumdis-2016-210104. Epub 2016 Dec 19. Ann Rheum Dis. 2017. PMID: 27993829 Free article. Clinical Trial.
Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.
Weinblatt ME, Kavanaugh A, Genovese MC, Jones DA, Musser TK, Grossbard EB, Magilavy DB. Weinblatt ME, et al. J Rheumatol. 2013 Apr;40(4):369-78. doi: 10.3899/jrheum.120923. Epub 2013 Feb 1. J Rheumatol. 2013. PMID: 23378467 Clinical Trial.
112 results